Mucin 21 is a key molecule involved in the incohesive growth pattern in lung adenocarcinoma.
MUC21
STAS
adenocarcinoma
cell adhesion
lung cancer
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
03
12
2018
revised:
25
06
2019
accepted:
07
07
2019
pubmed:
14
7
2019
medline:
1
10
2019
entrez:
14
7
2019
Statut:
ppublish
Résumé
Decreased cell adhesion has been reported as a significant negative prognostic factor of lung cancer. However, the molecular mechanisms responsible for the cell incohesiveness in lung cancer have not yet been elucidated in detail. We herein describe a rare histological variant of lung adenocarcinoma consisting almost entirely of individual cancer cells spreading in alveolar spaces in an incohesive pattern. A whole exome analysis of this case showed no genomic abnormalities in CDH1 or other genes encoding cell adhesion molecules. However, whole mRNA sequencing revealed that this case had an extremely high expression level of mucin 21 (MUC21), a mucin molecule that was previously shown to inhibit cell-cell and cell-matrix adhesion. The strong membranous expression of MUC21 was found on cancer cells using mAbs recognizing different O-glycosylated forms of MUC21. An immunohistochemical analysis of an unselected series of lung adenocarcinoma confirmed that the strong membranous expression of MUC21 correlated with incohesiveness. Thus, MUC21 could be a promising biomarker with potential diagnostic and therapeutic applications for lung adenocarcinoma showing cell incohesiveness.
Identifiants
pubmed: 31301084
doi: 10.1111/cas.14129
pmc: PMC6726699
doi:
Substances chimiques
Antigens, CD
0
CDH1 protein, human
0
Cadherins
0
MUC21 protein, human
0
Membrane Glycoproteins
0
Mucins
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3006-3011Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Am J Surg Pathol. 2017 Sep;41(9):1226-1230
pubmed: 28622180
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
Cancer Sci. 2017 Sep;108(9):1888-1896
pubmed: 28677170
Nat Rev Cancer. 2004 Feb;4(2):118-32
pubmed: 14964308
Cancer Sci. 2019 Sep;110(9):3006-3011
pubmed: 31301084
Ultrastruct Pathol. 1980 Apr-Jun;1(2):177-88
pubmed: 6262967
J Cardiothorac Surg. 2013 Apr 15;8:89
pubmed: 23587182
J Biol Chem. 2010 Jul 9;285(28):21233-40
pubmed: 20388707
J Thorac Oncol. 2015 May;10(5):806-814
pubmed: 25629637
J Clin Pathol. 2015 May;68(5):368-73
pubmed: 25731190
Cancer Res. 2015 Sep 1;75(17):3636-49
pubmed: 26141860
J Thorac Oncol. 2015 Jan;10(1):19-27
pubmed: 25319180
Lung Cancer. 2018 Sep;123:107-111
pubmed: 30089579
Glycobiology. 2012 Sep;22(9):1218-26
pubmed: 22611128
Glycobiology. 2008 Jan;18(1):74-83
pubmed: 17977904
Onco Targets Ther. 2015 Oct 27;8:3143-52
pubmed: 26604783
Jpn J Clin Oncol. 2015 Aug;45(8):755-66
pubmed: 25969565